The estimated Net Worth of Robert W Karr is at least $2.71 Mille dollars as of 16 September 2013. Robert Karr owns over 5,750 units of Idera Pharmaceuticals stock worth over $2,709 and over the last 19 years Robert sold IDRA stock worth over $0.
Robert has made over 1 trades of the Idera Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently Robert bought 5,750 units of IDRA stock worth $10,120 on 16 September 2013.
The largest trade Robert's ever made was buying 5,750 units of Idera Pharmaceuticals stock on 16 September 2013 worth over $10,120. On average, Robert trades about 198 units every 0 days since 2006. As of 16 September 2013 Robert still owns at least 6,299 units of Idera Pharmaceuticals stock.
You can see the complete history of Robert Karr stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 3 N. DUNLAP STREET, , MEMPHIS, TN, 38163.
Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... e Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.
Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Idera Pharmaceuticals executives and other stock owners filed with the SEC include: